Full-Time

Principal Scientist

In Vivo Pharmacology

RA Capital Management

RA Capital Management

Invests in healthcare, life sciences.

Compensation Overview

$170k - $185k/yr

+ Annual bonus + Long-term incentives

Cambridge, MA, USA

Hybrid

Hybrid schedule at the company headquarters in Cambridge.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
R
Pharmacology
Data Analysis

Get referred to RA Capital Management

See people who can refer or advise you

Requirements
  • A PhD in pharmacology, physiology, cell and molecular biology, or a related discipline with 7 or more years of relevant biopharmaceutical industry experience, or an M.S. or B.S. with commensurate experience.
  • Demonstrated ownership of in vivo pharmacology workstreams in discovery research and preclinical development, from target validation through candidate selection and development, with learning agility across disease biology.
  • Experience designing, outsourcing, and managing contract research organization-executed in vivo studies, including vendor qualification, protocol negotiation, budget and timeline ownership, on-site oversight when needed, and critical evaluation of external data.
  • Hands-on rodent experience with dosing by multiple routes, in-life assessment, and terminal collection, sufficient to design realistic protocols and challenge a contract research organization, plus experience designing or running non-human-primate studies.
  • In vivo phenotyping experience including quantitative imaging, histology and morphometry, tissue functional testing, and circulating biomarkers.
  • Strong quantitative and statistical fluency.
  • Working familiarity with Institutional Animal Care and Use Committee review, AAALAC-accredited facilities, and documentation supporting a defensible nonclinical package, sufficient for sponsor-side oversight of external studies.
  • Ability to guide junior scientists day to day or eagerness to grow into that responsibility.
  • A strategic, program-level perspective on in vivo pharmacology and motivation to expand that influence as the company grows.
  • Ability to operate independently, manage external partners with authority, and keep in vivo data reproducible, well-controlled, and decision-grade.
Responsibilities
  • Partner with the Director to set the staged in vivo pharmacology plan from target validation and proof of concept through dose response, duration of effect, candidate selection, and development, and own its execution.
  • Design contract research organization-executed rodent and non-human-primate studies, including controls, power, and prespecified endpoints, and author protocols and analysis plans.
  • Qualify and manage contract research organization partners for in vivo studies and outsourced analytics, including scope, budget, timeline, and quality, and serve as the day-to-day scientific contact from prestudy alignment through in-life monitoring and troubleshooting.
  • Select, qualify, and de-risk in vivo models by setting performance, variability, and effect-size expectations before pivotal studies.
  • Own the in vivo endpoint suite, including quantitative histology and morphometry, tissue-based pharmacodynamic readouts, circulating and tissue biomarkers, and omics readouts as needed.
  • Connect biodistribution and tissue exposure to pharmacodynamics and phenotype with the delivery and analytical chemistry groups, and design and interpret pharmacokinetic/pharmacodynamic studies establishing exposure-activity-efficacy relationships for dose, schedule, and duration.
  • Define the in vivo and translational biomarker plan carrying programs from research into development in alignment with overall program strategy.
  • Own sample logistics for in vivo studies, including receipt, cataloging, storage, chain of custody, and shipment to and from contract research organizations and analytical partners; specify required tissues and readouts for each study and hand samples to the in vitro scientist for execution.
  • Provide hands-on support for tissue processing so samples reach downstream analysis fit for purpose.
  • Benchmark candidates against standard-of-care and mechanistic comparators, and contribute to Investigational New Drug-enabling and larger-species study design and the nonclinical narrative as programs mature.
  • Provide sponsor-side data integrity, documentation, and animal-welfare oversight of external studies, including contract research organization and Institutional Animal Care and Use Committee review, chain of custody, and reproducibility, for an eventual regulatory package, and build the group’s in vivo record-keeping, data, and protocol templates.
  • Mentor junior team members and help grow the team as remits expand.
  • Bring in vivo results, program implications, and competitive-landscape intelligence into cross-functional and leadership discussions; help shape how in vivo findings reach the Board, investors, and partners; and contribute to publications, patents, and presentations.
Desired Qualifications
  • Experience in the company’s indication.
  • Experience developing translational biomarkers across research and development.
  • Experience with oligonucleotide therapeutics or other genetic medicines, especially interpreting pharmacology where exposure, target engagement, and phenotype are separated in time.
  • Comfort using R or Python for larger datasets.
RA Capital Management

RA Capital Management

View

RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.

Company Size

N/A

Company Stage

N/A

Total Funding

$39.9B

Headquarters

Boston, Massachusetts

Founded

2001

Get referred to RA Capital Management

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Equillium raised $35 million with RA Capital on March 13, 2026, extending pipeline optionality.
  • RA Capital opened 24 new positions in Q1 2026, showing aggressive deployment.
  • Its portfolio concentration in Ascendis, Septerna, and Vaxcyte creates outsized upside if winners compound.

What critics are saying

  • Biohaven and Yale won a $4 million judgment against RA Capital on August 25, 2026.
  • RA Capital sold $63.45 million of Septerna stock on August 12, 2026, signaling concentrated exit pressure.
  • Its Avilar trade-secret case exposes firm culture, and another verdict could damage dealflow with universities.

What makes RA Capital Management unique

  • RA Capital is evidence-based, multi-stage, and company-building, spanning healthcare and planetary health.
  • It backed 84 public positions and 103 private investments by mid-2026.
  • It still leads oversized financings, including Werewolf Therapeutics' $150 million round in August 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Company News

PR Newswire
Sep 3rd, 2026
Superluminal Medicines raises $60M Series B to advance rare obesity drug into Phase 1 trial

Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, with participation from Deep Track Capital and Perceptive Advisors alongside existing investors including RA Capital Management, Insight Partners, and NVIDIA. The Boston-based biotechnology company will use the proceeds to advance its lead programme — a selective MC4R agonist for rare genetic forms of obesity and hypothalamic obesity — into a Phase 1 clinical trial by the end of 2026. The funding will also support expansion of its GPCR-focused discovery platform. Superluminal integrates AI, machine learning, and structural biology to develop small-molecule therapies targeting G protein-coupled receptors for endocrine and cardiometabolic diseases. The company maintains a strategic collaboration with Eli Lilly for advancing GPCR-targeted therapeutics.

Morningstar
Aug 31st, 2026
Reframe Systems raises $40M to scale robotic microfactory network delivering homes 3x faster

Reframe Systems, a physical AI company industrialising homebuilding, has raised $40 million in venture-backed equity financing. The round was led by Energy Impact Partners, with participation from Counterpart Ventures, E12 Ventures, Global Brain, Thin Line Capital, Up Partners, LACI Impact Fund, and existing investors including Eclipse and VoLo Earth. The company builds small, highly automated microfactories near communities requiring housing. Its technology delivers homes three times faster and at 35% lower cost than traditional construction. Reframe has completed 10 homes and expects to deliver 114 additional units over the next year. The funding will support expansion of Reframe's microfactory network across North America. The company's new Massachusetts facility, FAB1, is designed to produce up to 500 multifamily units or 250 single-family homes annually with less than $5 million in equipment.

IT桔子
Aug 28th, 2026
Haobao Biopharmaceuticals raises $120M Series C for hepatitis B cure research

Haobao Biopharma, a Chinese biopharmaceutical company focused on developing hepatitis B treatments and oligonucleotide technologies, has secured $120 million in Series C funding. The round was led by a global strategic investor, with participation from new investor RA Capital Management and existing backers including Qiming Venture Partners, 6 Dimensions Capital, and Sherpa Healthcare Partners. The financing will support Phase III registration trials and commercialisation preparations for AHB-137, accelerate development of AHB-171 and next-generation combination therapies, and expand the company's oligonucleotide product pipeline. Haobao utilises its proprietary Med-Oligo platform and targeted delivery technologies to develop treatments across infectious diseases, immuno-oncology, and muscular disorders.

PR Newswire
Aug 28th, 2026
AusperBio raises $120M Series C to advance hepatitis B therapy towards commercialisation

AusperBio Therapeutics has closed a $120 million Series C financing round to advance its lead hepatitis B therapy, AHB-137, towards commercialisation. The financing was led by an unnamed strategic investor, with participation from new investor RA Capital Management and existing backers including HanKang Capital and Qiming Venture Partners. The proceeds will support AHB-137's Phase 3 registrational programme and commercialisation readiness. Funds will also accelerate development of AHB-171, the company's investigational siRNA candidate, and advance combination therapies for chronic hepatitis B. With this round, AusperBio has raised $360 million since 2024. The San Francisco-based biotech is developing oligonucleotide therapeutics targeting chronic hepatitis B, which affects an estimated 254 million people worldwide. AHB-137 is currently being evaluated in a Phase 3 trial in China.

MarketScreener
Aug 21st, 2026
Werewolf Therapeutics secures $150M in oversubscribed private placement led by RA Capital and Janus Henderson

Werewolf Therapeutics has entered into a securities purchase agreement to raise $150 million through a private placement ahead of a planned merger. The oversubscribed financing, scheduled to close on 21 August 2026, is co-led by RA Capital Management and Janus Henderson Investors. Other participants include Aberdeen Investments, Adage Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Arkin Bio Capital, Balyasny Asset Management, Patient Square Capital's Enavate Sciences, SilverArc Capital, Sphera Healthcare, and Woodline Partners, alongside other institutional buyers and existing investors. The company will sell common shares and pre-funded warrants with an exercise price of $0.001 per share. The purchase price per share will be determined before closing.